Feb

    Landslide Webinar Series: A Comparative Discussion of U.S. and Chinese On-Sale and Public Use Bars to Patentability

    1 PM EST

    This panel of experts will provide a comparative discussion on the similarities and differences between United States and Chinese patent law on pre-filing activities that can be patent precluding. Their discussion will include the U.S. Supreme Court’s 2019 Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. decision and the cross-jurisdictional implications of the decision. The panel will provide actionable insights that practitioners can leverage to manage U.S. business practice in China to avoid inadvertently triggering a patent bar.
    $195
    NON-MEMBERS
    $150
    MEMBERS
    $0
    SECTION MEMBERS
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    Join now to receive additional discounts
    Join and Buy – NOW
    United States patent law sets out a number of statutory bars, including the “on sale” and public use bars, that preclude an inventor from obtaining a patent if certain prohibited conduct is performed before the effective filing date of the patent application. Similar provisions exist under Chinese patent law, although the scope and limits of these provisions are not co-extensive with those in the United States. United States entities doing business in China and seeking patent protection there need to understand the interplay between the two different sets of legal standards and how to manage their pre-filing conduct accordingly.

    Event Details

    Duration

    90

    Format

    Web

    Date

    Feb 25, 2020

    2020-02-25T13:00:00-05:00 2020-02-25T14:30:00-05:00 Landslide Webinar Series: A Comparative Discussion of U.S. and Chinese On-Sale and Public Use Bars to Patentability This panel of experts will provide a comparative discussion on the similarities and differences between United States and Chinese patent law on pre-filing activities that can be patent precluding. Their discussion will include the U.S. Supreme Court’s 2019 Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. decision and the cross-jurisdictional implications of the decision. The panel will provide actionable insights that practitioners can leverage to manage U.S. business practice in China to avoid inadvertently triggering a patent bar.

    Sponsors

    Section of Intellectual Property Law

    Panelists

    Stephen Yang

    Weixian Zhu

    Moderators

    MCLE Information

    The ABA will seek 1.50 CLE general credit hours in 60-minute-hour states, and 1.80 general credit hours of CLE credit for this program in 50-minute states. Credit hours are estimated and are subject to each state’s approval and credit rounding rules.

    View - MCLE Details

    Deaf/Hard of Hearing Attendees

    CART (Communication Access Realtime Translation) service provides instant accessibility for the deaf and hard of hearing by delivering the spoken word as a realtime stream of text. CART service for this program is firewall-friendly and works in almost any network environment with Internet access, and is compatible with all major web browsers.

    Read more about - Webinar Features

    Related Products

    Related On-Demand CLE